Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 19:12:172.
doi: 10.3389/fnins.2018.00172. eCollection 2018.

Endocannabinoid System and Migraine Pain: An Update

Rosaria Greco  1 , Chiara Demartini  1 , Anna M Zanaboni  1   2 , Daniele Piomelli  3 , Cristina Tassorelli  1   2
Affiliations
Review

Endocannabinoid System and Migraine Pain: An Update

Rosaria Greco et al. Front Neurosci. .

Abstract

The trigeminovascular system (TS) activation and the vasoactive release from trigeminal endings, in proximity of the meningeal vessels, are considered two of the main effector mechanisms of migraine attacks. Several other structures and mediators are involved, however, both upstream and alongside the TS. Among these, the endocannabinoid system (ES) has recently attracted considerable attention. Experimental and clinical data suggest indeed a link between dysregulation of this signaling complex and migraine headache. Clinical observations, in particular, show that the levels of anandamide (AEA)-one of the two primary endocannabinoid lipids-are reduced in cerebrospinal fluid and plasma of patients with chronic migraine (CM), and that this reduction is associated with pain facilitation in the spinal cord. AEA is produced on demand during inflammatory conditions and exerts most of its effects by acting on cannabinoid (CB) receptors. AEA is rapidly degraded by fatty acid amide hydrolase (FAAH) enzyme and its levels can be modulated in the peripheral and central nervous system (CNS) by FAAH inhibitors. Inhibition of AEA degradation via FAAH is a promising therapeutic target for migraine pain, since it is presumably associated to an increased availability of the endocannabinoid, specifically at the site where its formation is stimulated (e.g., trigeminal ganglion and/or meninges), thus prolonging its action.

Keywords: FAAH inhibitors; endocannabinoid system; inflammation; migraine; trigeminal hyperalgesia.

PubMed Disclaimer

References

    1. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C. E., Brenner G. J., et al. . (2007). Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 10, 870–879. 10.1038/nn1916 - DOI - PMC - PubMed
    1. Ahn K., McKinney M. K., Cravatt B. F. (2008). Review enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev. 108, 1687–1707 10.1021/cr0782067 - DOI - PMC - PubMed
    1. Akerman S., Holland P. R., Goadsby P. J. (2007). Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J. Pharmacol. Exp. Ther. 320, 64–71. 10.1124/jpet.106.106971 - DOI - PubMed
    1. Akerman S., Holland P. R., Lasalandra M. P., Goadsby P. J. (2013). Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and “triptan” receptors: implications in migraine. J. Neurosci. 33, 14869–14877. 10.1523/JNEUROSCI.0943-13.2013 - DOI - PMC - PubMed
    1. Akerman S., Kaube H., Goadsby P. J. (2004). Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J. Pharmacol. Exp. Ther. 309, 56–63. 10.1124/jpet.103.059808 - DOI - PubMed